Drugs / GX-P1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04298749 | Aug 2020 → Jun 2021 | autoimmune disease | Genexine, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GX-P1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04298749 ↗ |
| Route | Intravenous | “After Single IV Infusion” NCT04298749 ↗ |